Resultado de búsqueda
Accufuser Continuous. Ideal for pain management, chemotherapy, antibiotic therapy and thalessemia. Available in 60ml, 100ml, 200ml and 300ml volumes. Flow rates from 0.5ml/hr – 250ml/hr. Accufuser Selectable Continuous. Select from four, eight or sixteen different flow rates. Available in 60ml, 100ml, 200ml, 300ml and 600ml volumes.
アキュフェーズ株式会社. 転売行為について. 最近、アキュフェーズ製品を正規取扱店から購入し、海外へ転売されるケースが多く報告されております。. アキュフェーズ製品は、国内仕様、海外仕様と分けて製造販売しており、国内仕様製品を海外で使用し ...
26 de nov. de 2020 · Accufuser is a medical device which enables cancer patients to receive chemotherapy treatment at home, as it provides mobility while the treatment is on-goin...
Technical Information. Accufuser ® 24 hour fresh filled, immediate use elastomeric pump for simple, safe and accurate drug delivery. Can be used in a hospital setting, or for longer-term outpatient treatment for better ambulatory patient care. Available in a range of sizes and flow rates and suitable for a variety of treatments and therapies.
31 de may. de 2018 · The ACCUFUSE Cervical System and cited predicate devices share similar basic design features and functions. Dimensions . The ACCUFUSE Cervical System is dimensionally similar to cited predicate devices. Sterilization The ACCUFUSE Cervical System is provided non-sterile and cited predicate devices are non-sterile for single use only.
Accufuser is the world’s number one latex free elastomeric balloon pump. It has many uses including long term delivery of local anaesthetic as either wound infiltration or as a continuous peripheral nerve block. In just over 5 years use in the UK, Accufuser has become the UK’s chosen, most used elastomeric pump for the delivery of post-op ...
Operating temperature: -55°C to +125°C. Insulation resistance: >20MΩ guaranteed (after fusing at rated voltage) Interrupting rating: 50A. Accu-Guard® II is a version of Accu-Guard® fuses for a wider range of current and voltage ratings. Constructed on alumina substrates, Accu-Guard® II fuses display superior electrical, mechanical and ...
